LONDON, Jan. 12, 2017 /PRNewswire/ -- ResMed (NYSE:RMD)
today announced new European research from Price Waterhouse Coopers
(PwC), revealing that patients with sleep apnea who use ResMed's
myAir have greater adherence to CPAP (continuous positive airway
pressure) therapy than those who don't.
myAir is ResMed's digital and online support program that
enables patients to track their own treatment and get personalized
coaching tips to support motivation.
The data, published today in a white paper, demonstrate that
myAir patients use their device an average 46 minutes longer per
night compared to other patients. Furthermore, the average
adherence to CPAP treatment for new patients in their first week of
treatment is 76% for myAir patients compared to 71% for other
patients.1
David Jones, Sleep Manager at
University Hospital of South Manchester,
United Kingdom, commented: "We know that around half of
patients are not compliant with their CPAP treatment; this is a
major concern for sleep treatment professionals.2 The
effects of poor treatment adherence are profound, not only because
of the impact on patients' quality of life, but also in terms of an
increased number of accidents and emergency visits,
hospitalizations and the resulting financial burden that this
places on healthcare systems. These latest findings confirm that
enabling patients to track and improve their CPAP device usage is
an important step towards long-term compliance and better patient
outcomes."
PwC's study, "Empowering the Sleep Apnoea Patient," analyzed
anonymous daily-usage data from over 23,000 patients in
Germany and the United Kingdom on CPAP or automatic positive
airway pressure (APAP) therapy for sleep apnea.1 The
patients were treated by sleep clinics and home care providers in
these two countries, and were all monitored via telemonitoring by
their nurse or physician. Over 1,800 of these patients were also
registered in myAir.
In addition to receiving data, PwC interviewed several clinics
and home care providers in the United
Kingdom, Germany and
Finland to further investigate the
positive influence of myAir on patients and clinics. Usage data and
anecdotal evidence were then analyzed for those patients who had
and hadn't registered for myAir.
Christian Käfling from PwC commented: "In recent
years, the introduction of telemonitoring has given sleep clinics
and home care providers a tool to proactively intervene to help
patients starting CPAP treatment. With myAir, telemonitoring has
been taken to the next level, and this research has now confirmed
that patients who use it show significantly and measurably better
adherence and usage than other patients."
Laurent Morin, ResMed's
EMEA Senior Medical Affairs Director, commented: "The myAir
online support program was developed based on principles of
behavioral therapy. It has been well documented that patient
engagement is key to successful treatment and that involving
patients in their treatment improves adherence. myAir's regular
reminders, tailored coaching and positive reinforcement offer a
valuable additional level of support to the care already provided
by sleep clinics."
PwC's study findings in Europe
are supported by recent research presented in the United States at CHEST 2016, the annual
meeting of the American College of Chest Physicians. The data
showed that patients who use a digital self-monitoring tool when
treating their sleep apnea with positive airway pressure (PAP) are
significantly more likely to continue using their therapy. The
observational study of more than 128,000 U.S. patients, the
largest-ever study of sleep apnea and digital connected care,
showed that more than 87% of PAP users were compliant on therapy
when using ResMed's myAir and AirView™, a clinical remote
monitoring tool, compared to 70% compliance for those using AirView
alone.3
Obstructive sleep apnea is a major public health problem across
Europe, and as with other
illnesses, poor adherence to treatment is a significant issue for
patients and the healthcare professionals who treat
them.3 Sleep apnea involves the recurrent partial or
complete collapse of the upper airway during sleep and is usually
associated with snoring, oxygen desaturation and sleep
fragmentation. CPAP devices prevent collapse of the upper airway by
maintaining continuous positive air pressure throughout inspiration
and expiration via a mask during sleep.5
Laurent Morin commented:
"While this study focused on CPAP users, we believe these results
may be applied more broadly in terms of the role that online tools
can have in improving medical treatment compliance overall."
About myAir™
myAir is available online at
https://myair.resmed.com to patients using ResMed's Air10™ devices,
and on the Apple App Store for Air10™ users in the United States. myAir allows patients to
track the progress of their therapy between visits to their
clinician, including a simple daily sleep score, details on key
treatment metrics and personalized coaching tips.
myAir™ reinforces the efforts of clinicians and helps patients
keep themselves informed and motivated, factors long considered to
play a role in effective treatment of sleep apnea and other medical
conditions.
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 2 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries.
ResMed.com | Facebook
| Twitter | LinkedIn
References
1. Price Waterhouse Coopers. Empowering the
sleep apnoea patient: A study of how myAir users behave better.
2016
2. Wolkove N et al. Long-term compliance with continuous positive
airway pressure in patients with obstructive sleep apnea. Can
Respir J. 2008;15(7):365–369
3. Crocker M et al. Patient Engagement Using New Technology to
Improve Adherence to Positive Airway Pressure Therapy. Chest
2016
4. European Lung White Book. Sleep breathing disorders.
http://www.erswhitebook.org/chapters/sleep-breathing-disorders/.
Accessed October 2016
5. Gharibeh T. and Mehra R. Obstructive sleep apnea syndrome:
natural history, diagnosis, and emerging treatment options.
Nat Sci Sleep
2010;2:233–255
Contacts:
|
|
|
|
|
|
For EMEA-APAC
Media
|
For
U.S.
Media
|
For Investors
|
Christine
Many-Lacoste
|
Alison
Graves
|
Agnes Lee
|
O: +33 6 21 83
7233
|
O:
858-836-6789
|
O: 858-836-5971
|
news@resmed.com
|
news@resmed.com
|
investorrelations@resmed.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/resmeds-myair-significantly-improves-adherence-to-cpap-therapy-in-patients-with-sleep-apnea-300389805.html
SOURCE ResMed Inc.